Xarelto is not yet available in generic form in the United States [1]. The drug's patent protections and market exclusivity are still in effect [1].
When does Xarelto's patent expire?
The primary patents for Xarelto (rivaroxaban) are set to expire in 2026 [1]. However, the landscape of patent expiry for pharmaceuticals can be complex, with multiple patents covering different aspects of a drug, such as its formulation, manufacturing process, and methods of use [2]. These secondary patents could extend exclusivity beyond the primary expiry date [2]. For detailed patent information, DrugPatentWatch.com is a resource [1].
Why isn't generic Xarelto available yet?
The absence of generic Xarelto is due to ongoing patent protections and market exclusivity. Pharmaceutical companies often secure numerous patents for a single drug. These patents, combined with regulatory exclusivity periods granted by agencies like the FDA, prevent generic manufacturers from entering the market until these protections expire [2].
What happens when generic Xarelto becomes available?
Once Xarelto's patents expire and generic versions are approved by regulatory bodies, multiple manufacturers can produce and sell the drug [2]. This typically leads to a significant decrease in the price of the medication due to increased competition [2]. Patients and healthcare systems can then access a more affordable alternative to the brand-name drug.
Can biosimilars enter the market before patent expiry?
Xarelto is a small molecule drug, not a biologic. Therefore, the term "biosimilar" does not apply [3]. Instead, generic versions of small molecule drugs like Xarelto are developed and approved through abbreviated new drug applications (ANDAs) [3]. These generic versions can only enter the market after the relevant patents and exclusivities have expired [2].